Cyclacel Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Bio Green Med Solution, formerly Cyclacel Pharmaceuticals, Inc., completed a strategic pivot in 2025, divesting its pharmaceutical assets and acquiring a Malaysian fire safety business, Fitters Sdn. Bhd., while facing ongoing financial challenges and a preferred stock delisting.
Bio Green Med Solution, formerly Cyclacel Pharmaceuticals, is undergoing significant restructuring, including a strategic focus on its plogo clinical program and a UK subsidiary liquidation, while facing substantial doubt about its ability to continue as a going concern.
10-K: Cyclacel Pharmaceuticals Navigates Strategic Shift Amidst Financial Challenges: A 2024 10-K Analysis
Cyclacel Pharmaceuticals' 2024 10-K filing reveals a company in strategic transition, focusing on its plogosertib program while addressing financial constraints through cost reductions and exploring strategic alternatives.
Cyclacel Pharmaceuticals has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and corporate governance.
Cyclacel Pharmaceuticals' 10-K filing details its capital stock, including common and preferred shares, and outlines key provisions related to dividends, voting rights, and liquidation preferences.